Navigation Links
Data Published in EuroIntervention Indicate that OrbusNeich's Genous™ Stent Is Safe with Very Short-Term Dual Antiplatelet Therapy

HONG KONG, Dec. 5, 2011 /PRNewswire/ -- OrbusNeich today announced that data published in the November issue of EuroIntervention indicate that the Genous Stent is safe when accompanied by only 10 days of dual antiplatelet therapy (DAPT).

In a multicenter trial involving 49 patients treated with Genous, no patient had died or had reached the study's primary endpoint of sudden cardiac death, myocardial infarction or angiographic evidence of stent thrombosis (ST) ascribable to the study stent at three-month follow-up. At this time, three patients had undergone repeat revascularization, with target lesion revascularization (TLR) in two patients.

"Despite this very short-term DAPT regimen, we observed only one case of ST at 26 days in a patient who had previously undergone percutaneous coronary intervention and stenting in the mid-left anterior descending artery with a bare metal stent," said Prof. Giuseppe M. Sangiorgi, corresponding author of the study, University of Rome Tor Vergata, Rome, Italy. "Coronary angiography disclosed thrombotic occlusion in this stent, while the nearby Genous Stent appeared patent and devoid of thrombus. This supports the case for Genous as a safe and effective treatment alternative for patients who cannot comply with a four-week-or-longer course of DAPT due to either bleeding risk or the need for a near-term invasive non-cardiac procedure."

Prof. Antonio Colombo, EMO GVM Centro Cuore Columbus and the Interventional Cardiology Unit, S. Raffaele Hospital, Milan, Italy, and principal investigator of the study, added, "The data obtained are encouraging and may justify the launch of a larger study powered to test the possibility to utilize the Genous stent with reduced duration of dual antiplatelet therapy."

The study included patients with de novo lesions in vessels able to receive a 2.5 mm Genous Stent. Patients received clopidogrel for 10 days, accompanied by lifelong aspirin administration. Seventy percent of the patients discontinued clopidogrel nine to 11 days after stenting. For the patients treated, the average age was 64.2 years, with 83.4 percent male patients and 18.7 percent of patients having been diagnosed with diabetes mellitus. Approximately half of the patients (55.1 percent) were diagnosed with multivessel disease, and the left anterior descending artery branches were the most commonly treated (61.2 percent of cases). A total of 55 Genous Stents were implanted.

About the Genous Technology

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 7,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo™ Dual Therapy Stent, the only dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit

Follow OrbusNeich on Twitter at, and learn more about the company and the Genous technology on OrbusNeich's YouTube Channel:




SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
2. Published Data Demonstrates Positron Emission Mammography Has Higher Sensitivity Than PET/CT
3. Dermatologist Amy Taub, MD, is Published in the Journal of Clinical and Aesthetic Dermatology
4. Butrans® (Buprenorphine) Transdermal System CIII Pivotal Phase 3 Data Published in the Journal of Pain and Symptom Management
5. Data Published in Circulation Journal Show OrbusNeichs Genous™ Stent Is Safe and Effective in Elderly Patients
6. Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
7. Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients
8. Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
9. NxStage: NIH Study Published in New England Journal of Medicine Adds to Growing Body of Evidence in Support of More Frequent Hemodialysis
10. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
11. LTCPA Study Quantifying Unused Medicare Part D Drugs in Skilled Nursing Facilities Published in The Consultant Pharmacist
Post Your Comments:
(Date:11/30/2015)... Medical Systems (NYSE: VAR ) has signed a Memorandum of ... the largest hospital chain in India , to ... country. The MoU was signed by Dr. K. Prabakar , ... Varian,s India managing director, in ... intends to deploy its Access to Care program by leveraging the ...
(Date:11/30/2015)... NAMUR , Belgium , Nov. 30, ... life sciences company focused on developing blood-based diagnostic tests for ... announced the Company will present at the LD Micro Conference, ... Los Angeles, CA. Attending from VolitionRx will ... and Scott Powell , Vice President of Investor Relations. ...
(Date:11/30/2015)... Mexico Healthcare and Life Sciences Report 2015 . --> ... Pharmaboardroom releases its new 98-page Mexico Healthcare and Life Sciences ... country of over 122 million people. --> Latin ... --> It offers companies, investors, policymakers, and stakeholders with an ... largest pharma and healthcare market in Latin America ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... by UPMC and KingMed Diagnostics researchers. Their review of ... that consultation with UPMC pathologists resulted in significantly altered treatment plans for more ...
(Date:11/30/2015)... ... 30, 2015 , ... ”Dying Words: The AIDS Reporting of Jeff Schmalz and ... to coincide with World AIDS Day. The multi-media project will be in audio documentary ... as he was dying of the disease. , A collaborative effort led by author, ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... promoting breast and prostate cancer education and prevention—is joining forces with the award-winning ... philanthropy and Hollywood elegance on December 7, 2015 at the Union League of ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... their exclusive channel partner for the Nutraceutical Specialties products into oral solid dosage ... effective immediately. , “We are pleased to announce our expanded distribution agreement ...
(Date:11/30/2015)... ... November 30, 2015 , ... California-based i2i ... years, announced today that Michigan-based Family Health Center (FHC) has selected i2iTracks as ... years, FHC was awarded the largest Affordable Care Act grant for Federally Qualified ...
Breaking Medicine News(10 mins):